NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial Average declined 0.72 percent to close at 24,834.41, while the S&P 500 Index declined 0.31 percent to close at 2,724.44. The Nasdaq Composite Index declined 0.21 percent to close at 7,378.46.
“For the moment, investors are taking a wait-and-see attitude with respect to the [trade] negotiations, especially with the other geopolitical issues weighing on the market,” said Jeff Kravetz, regional investment strategist at U.S. Bank Wealth Management, according to CNBC.
RDI Initiates Coverage on:
Forward Pharma A/S
Geron's stock jumped 12.12% Tuesday, to close the day at $4.07. The stock recorded a trading volume of 7,848,552 shares, which was above its three months average volume of 7,393,664 shares. In the last year, Geron's shares have traded in a range of 1.74 - 6.68. The share price has gained 133.91% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.73 is above its 200-day moving average of $2.77. Shares of Geron have gained roughly 7.39 percent in the past month and are up 126.11 percent year-to-date.
Access RDI's Geron Corporation Research Report at:
On Tuesday, shares of Forward Pharma recorded a trading volume of 1,389,564 shares, which was above the three months average volume of 118,433 shares. The stock ended the day 88.18% higher at $4.14. The share price has fallen 86.2% from its 52 week high with a 52 week trading range of 1.63 - 30.00. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.22 is below its 200-day moving average of $3.33. Shares of the company are trading at a Price to Earnings ratio of 0.21. Shares of Forward Pharma have gained roughly 92.92 percent in the past month and are up 11.14 percent year-to-date.
Access RDI's Forward Pharma A/S Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.